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Background: Anxiety disorders increase risk of future cardiovascular disease (CVD) and
mortality, even after controlling for confounds including smoking, lifestyle, and socioe-
conomic status, and irrespective of a history of medical disorders. While impaired vagal
function, indicated by reductions in heart rate variability (HRV), may be one mechanism link-
ing anxiety disorders to CVD, prior studies have reported inconsistent findings highlighting
the need for meta-analysis.
Method: Studies comparing resting-state HRV recordings in patients with an anxiety
disorder as a primary diagnosis and healthy controls were considered for meta-analysis.
Results: Meta-analyses were based on 36 articles, including 2086 patients with an anx-
iety disorder and 2294 controls. Overall, anxiety disorders were characterized by lower
HRV [high frequency (HF): Hedges’ g =−0.29. 95% CI: −0.41 to −0.17, p<0.001; time
domain: Hedges’ g =−0.45, 95% CI: −0.57 to −0.33, p<0.001] than controls. Panic
disorder (n=447), post-traumatic stress disorder (n=192), generalized anxiety disor-
der (n=68), and social anxiety disorder (n=90), but not obsessive–compulsive disorder
(n=40), displayed reductions in HF HRV relative to controls (all ps<0.001).
Conclusion: Anxiety disorders are associated with reduced HRV, findings associated with
a small-to-moderate effect size. Findings have important implications for future physical
health and well-being of patients, highlighting a need for comprehensive cardiovascular
risk reduction.
Keywords: heart rate variability, anxiety, anxiety disorders, meta-analysis, treatment, cardiovascular disease
INTRODUCTION
Anxiety disorders are the most prevalent psychiatric disorders (1),
and one of the most costly (2). Anxiety disorders also increase risk
of cardiovascular disease (CVD) three- to fourfold, after account-
ing for sex, substance use,and depression (3,4) while risk of cardiac
mortality is increased twofold (5–7). Here, we examine the impact
of the anxiety disorders on a psychophysiological marker of health
and well-being, heart rate variability (HRV). Previous studies are
characterized by contradictory reports, highlighting the need for
a meta-analysis of previously published findings.
Heart rate variability is the fluctuation of heart period over
time, commonly measured by electrocardiogram (ECG), and is an
important marker of psychological well-being, general cardiovas-
cular health, and is a major predictor of mortality (8–10). The
mechanism underpinning the relationship between mental and
physical health may, in part, relate to impairment in vagal nerve
activity leading to a dysregulation of inflammatory processes (11,
12). Reductions in resting-state HRV reflect decreases in vagal out-
put. We have now published several meta-analyses reporting HRV
reductions in depression (13) and alcohol dependence (14). To
date, no meta-analysis has been published on HRV and the anxiety
disorders; this is a surprising observation considering that anxiety
is an early marker of cardiovascular risk and a robust predictor of
CVD and sudden cardiac death, independent of demographic risk
factors, biological risk factors, and health behaviors (5, 6, 15).
There are a variety of reasons to expect that HRV will be reduced
in the anxiety disorders. According to the neurovisceral integra-
tion model (16), efferent nerve fibers from the pre-frontal cortex
moderate parasympathetic activity and vagal nerve inhibition
of cardiac activity, where proper vagus nerve regulation medi-
ates inflammatory processes that lead to a variety of pathologies,
including type-II diabetes (17), clinical depression (18), coronary
heart disease (19), and neurodegenerative diseases (20). The neu-
rovisceral integration model also characterizes a detailed network
of specific neural structures that enable humans to adaptively
respond to environmental, physiological, behavioral, cognitive,
and emotional influences. In this model, a healthy autonomic ner-
vous system is characterized by high levels of adaptive variability,
or rheostasis (21, 22). An illustration of this point can be seen in
the observation that a healthy cardiorespiratory system is char-
acterized by complex oscillation patterns in heart period (or high
HRV) whereas a diseased system displays little to no variability (9).
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A key feature of the neurovisceral integration model is the central
autonomic network (CAN), a network of brain regions that coor-
dinates autonomic, endocrine, and behavioral responses in goal
directed action and in adaptation to environmental challenges.
The integrity of this network is compromised in anxiety; sympa-
thoexcitatory responses are unable to be effectively inhibited, lead-
ing to behavioral inflexibility. The neurovisceral integration model
also links hypervigilance and worry – features observed in all the
anxiety disorders (23) – to reductions in HRV. Chronic reductions
in resting-state HRV appear to be associated with worry (24–27)
and pathological worry has been implicated in the development
of CVD and CVD risk factors, where HRV is one mechanism of
cardiopathogenesis (28). Further, HRV reductions may also be
observed during phasic forms of anxiety, such as panic sympto-
matology (29–31). Given that many treatments aim to address
these features of anxiety, it may be that successful treatments
may positively impact on autonomic functioning. Interventions
that improve HRV (e.g., exercise) may also help to ameliorate
hypervigilance and worry (32–34). These bidirectional associa-
tions are supported by reciprocal connections between brain and
body (16, 35).
Many studies have reported reduced HRV in people with
anxiety disorders. The majority of studies in the literature have
focused on panic disorder (PD); over 20 studies have been con-
ducted to date on HRV in PD patients. Researchers have also
reported on the impact of post-traumatic stress disorder (PTSD),
generalized anxiety disorder (GAD), obsessive–compulsive disor-
der (OCD), social anxiety disorder (SAD), specific phobias, and
mixed/grouped anxiety disorders on HRV, with equivocal results
(see Table 1 below for a summary). The reason for the inconsis-
tency in results across studies is unclear, although two possible
explanations present themselves: small sample size and common
confounds including psychiatric and medical co-morbidity, as well
as medication use.
Overall, the impact of anxiety and their treatments on HRV
is mixed. While many studies report significant HRV reductions
in anxiety disorder patients, some report no significant findings.
This pattern of results could be considered to reflect an under-
lying negative “true” relationship, a hypothesis we set to test
meta-analytically. A narrative review published 7 years ago (21)
comprehensively reviewed studies on the impact of the anxiety
disorders on HRV, concluding that “reports of aberrant HRV fea-
tures of panic outnumber negative findings by a ratio of greater
than 6:1” [(21) p.191]. A limitation of this approach is that it
does not take into account the magnitude of the effects, whether
effect sizes are consistent across studies, or the possibility that non-
significant outcomes may have been afflicted by insufficient power.
Conversely, meta-analysis provides a robust statistical method of
synthesizing effect sizes across studies, and is a valuable tool for
clarifying contradictory findings. In summary, there is a need
for an up-to-date systematic review of the literature given the
important implications that reductions in HRV may have over
the long term.
In the present study, we sought to determine the impact
of anxiety on resting-state HRV, a psychophysiological marker
of health and well-being, minimizing variation across studies.
To our knowledge, the present report is the first to address
this question using meta-analytic methodology. Specifically, we
examine whether patients with any anxiety disorder exhibit reduc-
tions in HRV relative to healthy controls, and determine the size of
this effect across specific anxiety disorders. We hypothesized that
anxiety patients overall would display reductions in HRV relative
to healthy participants.
MATERIALS AND METHODS
SEARCH CRITERIA
The search strategy followed guidelines outlined in the pre-
ferred reporting items for systematic reviews and meta-analyses
(PRISMA) (76) statement. Peer-reviewed studies were located
in Embase, MEDLINE, and PsychINFO, with all relevant com-
binations of the following words and phrases: “heart rate vari-
ability,” “HRV,” “vagal,” “parasympathetic,” “autonomic nervous
system,” “generalized anxiety disorder,” “generalized anxiety dis-
order,” “GAD,” “obsessive-compulsive disorder,” “obsessi*,” “com-
pulsi*,” “OCD,” “panic disorder” “panic disorder with* agora-
phobia,” “PD,” “post-traumatic stress disorder,” “PTSD,” “acute
stress disorder,” “social anxiety disorder,” “SAD,” “social phobi*,”
“specific phobia,” and “anxi*.” In addition to these electronic
searches, each report’s citation list was examined for additional
studies. The search was performed during October 2013, with no
limitation on time-period. The inclusion criteria were: (1) the
comparison of HRV in patients with a diagnosis of an anxiety
disorder as defined by DSM-III (77), DSM-III-R (78), DSM-IV
(79), DSM-IV-TR (80), or ICD-10 (81), and a control group
free from psychiatric diagnosis; (2) satisfactory reporting of sta-
tistics (i.e., mean, SD, p, t, r, or F value); and (3) the study
was written in English. No limitations were made concerning
medication status, physical illness including CVD, or disorder
co-morbidity; however these factors were included in follow-up
moderator analyses. All potentially relevant manuscripts were
independently reviewed by two investigators (JAC and DSQ) and
areas of disagreement or uncertainty were adjudicated by a third
investigator (AHK).
PROCEDURE
Meta-analyses were conducted to answer the primary research
question of whether patients with anxiety disorders exhibit reduc-
tions in resting-state HRV relative to controls, and to determine
the size of this effect across specific anxiety disorders. HRV is
recorded under short-term (2 min to 1 h) or long term (24 h) con-
ditions, both of which provide reliable indicators of autonomic
functioning and are robust predictors of mortality (8) and future
cardiac events (82). A variety of HRV measures are reported in
the literature, which generally fall under time domain (TD) and
frequency domain (83–85). A third domain of HRV is respiratory
sinus arrhythmia (RSA), which reflects parasympathetic nervous
system activity by indexing the coupling of heart period and respi-
ration. The TD measures extracted for analysis included RMSSD,
SDNN, pNN50, and SDANN. If more than one TD measure was
reported RMSSD was given preference, followed by SDNN, pNN50
then SDANN. RMSSD was given preference as it closely represents
parasympathetic activity and is highly correlated with the high
frequency (HF) HRV component. Of the frequency domain HRV
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Table 1 | Summary of studies reporting comparisons in HRV between patients with anxiety disorders and controls.
Study HRV
measures
Participants
with anxiety
disorder
Healthy
control
subjects
Sig. diff
between
groups
Major finding
PANIC DISORDER (PD)
Alvargenga et al. (36)a HF, LF 25 20 + Lower HF power in PD compared with controls
Chang et al. (37)a HF, LF, TD 48 202 + Lower HRV in PD patients compared with controls in all measures
Cohen et al. (30)a HF, LF 11 25 + Lower HF power and higher LF power in PD relative to controls
Garakani et al. (31)a HF, LF, TD 43 11 + Lower PNN 50% in PD relative to controls. HF and LF power
non-significant between groups
Ito et al. (38)a HF, LF 8 13 − No differences in HF and LF power between PD and controls
Kang et al. (39)a HF, LF, TD 45 30 + Lower HF power and higher LF power in PD relative to controls.
All TD measures non-significant
Kikuchi et al. (40)a HF, LF, TD 17 15 − No differences between PD and controls on all measures
Lavoie et al. (41)a HF, LF 20 22 − LF and HF power non-significant (but lower LF/HF ratio in PD
relative to controls)
Martinez et al. (42)a HF, LF, TD 30 10 + Higher LF power and LF/HF ratio in PD relative to controls; lower
PNN50 in PD
McCraty et al. (43)a HF, LF 38 38 + LF/HF ratio and LF power lower in PD relative to controls; higher
HF power in PD
Melzig et al. (44)a TD 9 15 + Lower RMSSD in PD relative to controls
Middleton and Ashby (45)a TD 12 12 − No differences in HF power between groups. Reduced HR
standard deviation in PD
Pittig et al. (29)a HF 39 39 + Lower HF HRV in PD patients
Prasko et al. (46)a HF, LF 52 104 + Lower LF/HF ratio and SDNN in PD relative to controls
Slaap et al. (47)a HF 24 24 − No differences on any HRV measure between PD and controls
Wang et al. (48)a HF, LF 27 20 − No difference between PD patients and controls
Wise et al. (49)a TD 30 20 + Lower R–R variance in PD compared to controls
Yeragani et al. (50)a TD 21 21 + Lower HR standard deviation in PD relative to controls
Yergani et al. (51)a HF, LF 6 11 − No differences between PD and controls on all measures at
baseline
Asmundson and Stein (52)b RSA 15 15 − No differences in parasympathetic nervous system function
between PD and controls
Blelchert et al. (53)b RSA 26 32 − No differences in parasympathetic nervous system function
between PD and controls
Klein et al. (54)b HF 10 14 + Lower HF power in PD relative to controls
Petrowski et al. (55)b TD 14 14 − No differences in TD measures between PD and controls
Yergani et al. (56)b TD 29 23 − Lower absolute ULF in PD relative to controls
POST-TRAUMATIC STRESS DISORDER (PTSD)
Agorastos et al. (57)a TD 7 8 − Reduced HRV in PTSD patients, but did not reach significance
Cohen et al. (58)a HF, LF 9 9 + Lower HF and higher LF power in PTSD relative to controls
Hauschildt et al. (59)a HF, LF, TD 26 18 + Lower HF power and RMSSD in PTSD relative to controls. LF
power non-significant
Keary et al. (60)a HF, LF 20 20 − No differences at baseline between PTSD and controls
Lakusic et al. (61)a HF, LF, TD 34 34 + Lower HF power and RMSSD in PTSD relative to controls; higher
LF power in PTSD
(Continued)
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Table 1 | Continued
Study HRV
measures
Participants
with anxiety
disorder
Healthy
control
subjects
Sig. diff
between
groups
Major finding
Norte et al. (62)a TD 19 16 + Lower HRV in PTSD patients
Shah et al. (63)a HF, LF 31 385 + Lower HF and LF HRV in PTSD patients
Tucker et al. (64)a HF, LF 13 32 + Higher LF power and LF/HF ratio in PTSD relative to controls
Wahbeh and Oken (65)a HF, LF 52 29 + Reduced HF and LF in PTSD patients relative to controls
Blechert et al. (53)b RSA 23 32 + Lower parasympathetic nervous system function in PTSD relative
to controls
Cohen et al. (30)b HF, LF, TD 14 25 + Lower HF and higher LF power in PTSD relative to controls
Cohen et al. (66)b HF, LF 16 16 + Lower HF and higher LF power in PTSD relative to controls
Shaikh Al Arab et al. (67)b TD 7 11 + Lower RMSSD in PTSD relative to controls
GENERALIZED ANXIETY DISORDER (GAD)
Hammel et al. (68)a HF, LF, TD 16 19 − No differences in any HRV measure between GAD patients and
controls
Lyonfields et al. (24)a TD 15 15 + Lower mean successive differences in GAD relative to controls
Pittig et al. (29)a HF 26 39 − Borderline lower HF HRV in GAD patients (p=0.06)
Thayer et al. (25)a HF, LF, TD 34 32 + Lower HF power in GAD compared to control
Kollai and Kollai (69)b RSA 19 18 + Lower RSA in GAD compared to control
OBSESSIVE–COMPULSIVE DISORDER (OCD)
Pittig et al. (29)a HF 17 39 + Lower HF HRV in OCD patients
Slaap et al. (47)a HF, LF 26 24 − No differences between OCD and controls
SPECIFIC PHOBIA
Bornas et al. (70)a HF, LF, TD 61 58 + Difference in TD HRV between flight phobics and controls, but not
HF and LF HRV
SOCIAL ANXIETY DISORDER
Alvares et al. (71)a HF, LF, TD 53 53 + Significant reductions in HF HRV and RMSSD for social phobics
relative to controls
Gaebler et al. (72)a HF 21 21 + Lower HF HRV in social phobics
Pittig et al. (29)a HF 29 39 + Lower HF HRV in social phobics
Asmundson and Stein (52)b RSA 15 15 − No differences in parasympathetic activity between social phobics
and controls
MIXED ANXIETY DISORDER
Einvik et al. (73)a HF, LF, TD 20 231 − No differences in HF or LF power, or SDNN between anxiety
patients and controls
Licht et al. (74)a TD, RSA 1159 616 + Lower SDNN and RSA in anxiety patients relative to controls.
Effect disappears when controlling for psychotropic use
Martens et al. (75)a HF, LF, TD 7 59 + Lower RMSSD in anxiety patients relative to controls
TD, time domain; HF, high frequency; LF, low frequency; RSA, respiratory sinus arrhythmia.
aStudy included in meta-analysis.
bStudy excluded from meta-analysis.
measures, HF HRV reflects parasympathetic (vagal) nervous sys-
tem output (86) and is the most commonly reported measure of
HRV in the anxiety literature. The frequency domain measures
extracted were high and low frequency (LF) HRV. There is an
ongoing debate as to the interpretation of LF HRV (85, 87), and
consequently there are sound arguments against the utility and
meaningfulness of the oft reported measure LF/HF ratio (88, 89).
As such, this measure was not extracted. There are also a number
of non-linear methods used to evaluate HRV (85); however, anx-
iety studies using non-linear methods [e.g., Ref. (71, 90)] have
not accumulated to the point that meta-analysis is feasible. Using
moderator analyses, we examined possible impacts of known
confounds, including medical and psychiatric co-morbidity as well
as medication status. Moderator analyses also examined the poten-
tial impact of study characteristics (i.e., diagnostic criteria) on
HRV parameters. Finally, while short and long-term assessments
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of HRV have been found to be significantly related to one another,
the reported correlation coefficients are rather weak (91). Thus,
moderator analyses also compared studies reporting short-term
versus long-term recordings to examine if recording method
impacted the results.
META-ANALYSIS STATISTICS
Meta-analyses were based on a single effect size of a standard-
ized mean. Values were transformed from available statistics (e.g.,
means and SDs) to determine a standardized effect size, Hedges’
g, using the computer software package comprehensive meta-
analysis (92). Hedges’ g is related to Cohen’s d and can be inter-
preted using the same conventions: small (0.2), medium (0.5), and
large (0.8) (93). An added benefit of Hedges’ g is correction for
biases found in small sample sizes. The random-effects model was
applied in the present meta-analysis, thereby adopting a conserva-
tive approach that assumes true effect size may vary from study to
study, allowing results to be generalized to populations beyond the
study samples (94). To measure homogeneity of effect sizes across
studies, the Q statistic was examined. A significant Q statistic is
indicative of dissimilar effect sizes across studies; suggesting that
methodological or population sample differences might be intro-
ducing variance in findings across studies (95). To complement
the Q test, we also calculated the I 2 statistic, which provides an
index of the degree of heterogeneity across studies, where I 2 sig-
nifies the percentage of the total variability in effect sizes due to
between-studies variability, and not due to sampling error within
studies. Percentages of around 25% (I 2= 25), 50% (I 2= 50), and
75% (I 2= 75) may be interpreted as low, medium, and high het-
erogeneity, respectively (96). Begg’s adjusted rank correlation test
(97) and Egger’s regression test (98) were used to assess publi-
cation bias. The Duval and Tweedie “Trim and Fill” procedure
(99) was used to adjust for any suspected publication bias using
a random-effects model. This procedure imputes the “missing”
studies and recalculates the overall effect size with the inclusion of
hypothetical studies.
RESULTS
INCLUDED STUDIES
The search of electronic databases for HRV research in anxiety
revealed 4149 studies as at October 2013; these were reduced to
194 after examining study abstracts and then to 36 after reviewing
the study methods (Figure 1).
IMPACT OF ANXIETY DISORDERS ON HRV
High frequency HRV was reduced in participants with any anxiety
disorder, regardless of specific diagnosis, relative to healthy con-
trols [Hedges’ g =−0.29 (−0.41 to−0.17); SE= 0.06; p< 0.001],
a finding associated with a small effect size. Egger’s regression
test (p= 0.43) indicated no evidence of publication bias. The Q
statistic was significant (Q= 51.39, p= 0.002) indicating study
heterogeneity (I 2 statistic= 35.8%). To examine findings in fur-
ther detail, we examined effect sizes in specific anxiety disorders
(see Table 2, which displays the summary effect sizes for each dis-
order; and Supplementary Material, which displays the relevant
forest plots for each analysis.). HF HRV was significantly reduced
in patients with GAD and SAD, findings associated with a mod-
erate effect size, as well as in those with PD and PTSD, findings
Embase, MEDLINE, and PsychINFO 
search with duplicates removed
4149 articles
194 articles
36 articles included
3955 articles were excluded 
after a review of the titles and 
abstracts
158 articles were excluded 
after full text review based on 
inclusion criteria (see section 
2.1)
FIGURE 1 | Selection of articles for inclusion. Note: diagnostic grouping
of studies do not add to 36 due to some studies reporting on multiple
diagnoses.
associated with a small effect size. Findings for OCD, specific pho-
bia, and those studies in which anxiety disorders were grouped
were all non-significant.
Moderator analysis revealed no significant differences across
anxiety disorder diagnoses (Q= 6.83; p= 0.34). There was no
evidence of heterogeneity between studies using different diag-
nostic criteria including DSM-III, DSM-IV, or ICD-10 (Q= 0.85,
p= 0.65), nor was there heterogeneity for use of medication
(Q= 0.1, p= 0.75), co-morbid psychiatric diagnoses (Q= 0.29,
p= 0.59), or co-morbid medical disorders (Q= 0.004, p= 0.95).
No evidence of heterogeneity between studies using short-
term versus long-term recordings was obtained either (Q= 2.92,
p= 0.09).
Low frequency HRV did not differ between participants with
any anxiety disorder and controls [Hedges’ g =−0.08 (−0.31–
0.15); SE= 0.09; p= 0.49]. Egger’s regression test (p= 0.001)
indicated evidence of publication bias and the Q statistic was sig-
nificant (Q= 85.02, p< 0.001) (I 2 statistic= 75.3%). However,
LF HRV did not differ for any anxiety disorder relative to healthy
controls (Table 2). Moderator analyses revealed that LF HRV did
not differ across anxiety disorders (Q= 3.73, p= 0.59); nor was
there any evidence of heterogeneity from other factors.
Time domain HRV was reduced in participants with any anxi-
ety disorder relative to controls [Hedges’ g =−0.7 (−1.45– 0.05);
SE= 0.38; p= 0.07], a finding associated with a moderate effect
size. While this finding was at trend levels, the overall Q statistic was
significant (Q= 1027.39, p< 0.001) and the I 2 statistic was 98.2%
indicating high variance between studies, highlighting a need to
further inspect these data. Egger’s regression test (p< 0.001) also
indicated evidence of publication bias. After the exclusion of a clear
outlier (74) (see Supplementary Material), HRV was significantly
reduced in those with anxiety disorders relative to healthy controls
[Hedges’ g =−0.45 (−0.57 to −0.33); SE= 0.06; p< 0.001], and
there was no longer evidence of heterogeneity between studies
(Q= 18.46, p= 0.43, I 2 statistic= 2.5%). Egger’s regression test
still revealed evidence of publication bias (p= 0.01). TD HRV was
significantly reduced in patients with PTSD and GAD, findings
associated with a moderate effect size, as well as in PD, SAD, and
Specific Phobias, findings associated with a small effect size (see
Table 2). Follow-up moderator analyses revealed no difference in
summary effect sizes between disorders (Q= 2.8, p= 0.73). No
evidence of heterogeneity from other factors was observed.
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Table 2 | Meta-analysis results of HRV in specific anxiety disorders.
Meta-analysis performed No. of
data sets
Number of anxious
participants
Number of control
participants
Comparison of anxious and control participants
Effect size (95% CI) SE of summary
effect size
p value
All disorders
Time domain HRVa 20 1615 1402 −0.70 (−1.45 to −0.05) 0.38 0.07
HF HRV 34 915 1659 −0.29 (−0.41 to −0.17) 0.06 <0.001
LF HRV 22 715 1115 −0.08 (−0.31 to 0.15) 0.09 0.49
Panic disorder
Time domain HRV 8 264 243 −0.41 (−0.68 to −0.15) 0.13 0.002
HF HRV 16 437 520 −0.22 (−0.42 to −0.02) 0.10 0.030
LF HRV 12 360 426 −0.11 (−0.47 to 0.25) 0.18 0.544
Post-traumatic stress disorder
Time domain HRV 4 86 76 −0.69 (−1.00 to −0.38) 0.16 <0.001
HF HRV 7 192 525 −0.29 (−0.58 to −0.001) 0.15 0.049
LF HRV 6 183 516 −0.04 (−0.51 to 0.42) 0.24 0.854
Generalized anxiety disorder
Time domain HRV 3 65 66 −0.55 (−0.89 to −0.21) 0.18 0.002
HF HRV 3 68 90 −0.56 (−0.87 to −0.25) 0.16 <0.001
LF 1 16 19 0.50 (−0.16 to 1.16) 0.34 0.140
Obsessive–compulsive disorder
HF HRV 2 40 63 −0.28 (−0.84 to 0.28) 0.29 0.328
LF HRV 1 26 24 −0.08 (−0.63 to 0.47) 0.28 0.773
Social anxiety disorder
Time domain HRV 1 53 53 −0.40 (−0.79 to −0.02) 0.20 0.038
HF HRV 3 90 113 −0.47 (−0.74 to −0.20) 0.14 0.001
LF HRV 1 53 53 −0.25 (−0.63 to 0.13) 0.19 0.205
Specific phobia
Time domain HRV 1 61 58 −0.38 (−0.74 to −0.02) 0.18 0.037
HF HRV 1 61 58 −0.05 (−0.41 to 0.31) 0.18 0.784
LF HRV 1 61 58 −0.05 (−0.41 to 0.31) 0.18 0.782
Mixed anxiety
Time domain HRVb 3 1086 906 −1.52 (−4.13 to 1.08) 1.33 0.251
HF HRV 2 27 290 −0.24 (−0.85 to 0.37) 0.31 0.442
aLicht et al. (74) included, however, this study was not included in the final analysis. Without the inclusion of this large outlier, overall TD effect becomes significant
[Hedges’ g=−0.45 (−0.57 to −0.33); SE= 0.06; p<0.001].
bLicht et al. (74) included.
DISCUSSION
Meta-analysis revealed that anxiety disorders are associated with
significant reductions in HRV, effects associated with a small-to-
moderate effect size. Importantly, medication use and medical
and psychiatric co-morbidity did not impact these findings. The
present study revealed that PD, PTSD, GAD, and SAD displayed
significant reductions in TD and HF HRV, findings associated with
a moderate effect size. Specific phobias also displayed reductions
in TD HRV, although these findings were associated with a small
effect size. Effects relating to OCD and studies that grouped anxiety
disorders were not associated with significant reductions. Further,
our results suggest that anxiety disorders do not adversely impact
on LF, perhaps highlighting the specificity of effects on the PNS,
which is better reflected in HRV measures including RMSSD and
HF. Considering that reductions in HRV predicts adverse future
outcomes including CVD and sudden cardiac death (9, 10, 15), our
findings have important implications for future physical health of
patients with a diagnosis of anxiety, and PD, PTSD, GAD, and SAD
in particular.
There are a number of possible explanations why OCD, in con-
trast with the other anxiety disorders, was not associated with
reductions in HRV. First, the sample size was limited (n= 40).
Second, there was inconsistency in reports between the two stud-
ies reporting on HRV and OCD. Slaap et al. (47) found that
HF HRV parameters did not differ between patients and con-
trols. Pittig et al. (29), however, was the first study to report
reduced HF HRV in OCD patients relative to controls. As the
authors noted, it is possible that results in the latter study could
be accounted for by psychotropic medication use (11 of 17 OCD
patients reported current medication use). The inconsistent results
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cited above mirror the inconsistencies in results on OCD patients
and other indices of autonomic activity (100–103). In sum, more
research is needed before firm conclusions can be drawn on cardiac
autonomic functioning in these patients.
Anxiety, in all its forms, can be seen as a failure of inhibition
involving reduced capacity to inhibit cognitive (e.g., apprehen-
sion, vigilance, and worry), affective (e.g., panic), behavioral (e.g.,
avoidance), and physiological (e.g., increased HR) responses, lead-
ing to reduced vagal outflow and lowered HRV. The prominent
reductions in HRV observed here (with the exception of OCD) are
in line with previous theoretical models. The neurovisceral inte-
gration model (16, 21) highlights a role for the prefrontal cortex in
inhibitory function via a vagally mediated pathway, which can be
indexed by HRV. In addition, the polyvagal theory (35) highlights
a role for the myelinated vagus in promoting social engagement
and communication, and cultivating relaxed behavioral states by
inhibiting sympathetic tone on the heart and dampening the
hypo-pituitary–adrenal axis. When the environment is perceived
as safe, vagal outflow increases, promoting regeneration, home-
ostatic functions, and social behavior. Critically, impairment of
these neural processes leads to a difficulty in detecting whether
environments are safe or whether people are trustworthy, which
in turn may play a role in the development of the anxiety disorders.
Polyvagal theory may therefore help explain the link between anx-
iety and reduced capacity for inhibition as well as reduced social
engagement characteristic of individuals with anxiety.
Our current findings have important implications for the estab-
lished link between reduced HRV, anxiety, and health. All anxiety
disorders exhibit greater threat-related attentional biases relative
to controls (23). This perseverance results in chronically high levels
of corticotropin releasing factor (a hormone and neurotransmit-
ter released in response to stress) and high basal levels of cortisol,
leading to chronically withdrawn parasympathetic activity (i.e.,
low vagal tone) (104). Additionally, chronic worriers may also
display poor cardiac autonomic regulation in response to non-
threatening cues (105). It is also possible that impaired vagal
function, which usually plays an important role in regulating the
hypothalamic–pituitary–adrenal axis (106), leads to heightened
activation of stress responses. The inability to disengage from
threat detection heightens activation of the sympathetic nervous
system underpinned by a chronic withdrawal of parasympathetic
activity (and long-term reductions in HRV). This chronicity may
in turn contribute to chronic withdrawal of the parasympathetic
nervous system, and subsequent impairment in the cholinergic
anti-inflammatory reflex (107), leading to an increase in a host
of conditions including diabetes, obesity, and CVD (9, 10). A
prospective study on worry and future cardiac health has reported
that high levels of worry alone increase the risk of future myocar-
dial infarction two to threefold (108). Given the clear impact of
chronic worry on future cardiac health, it is especially concerning
given that anxiety patients may suffer for as long as 5–10 years
before diagnosis and treatment (109). Given the potential health
implications of suffering from an anxiety disorder, there are clear
implications concerning the importance of discovering whether
successful treatments have been shown to increase HRV in anxiety
disordered patients.
Previous research concerning the question of the impact of
treatment for anxiety on HRV can broadly be grouped into studies
that investigated the impact of psychotropic and non-psychotropic
therapies. Concerning psychotropic treatments, two studies have
investigated the impact of pharmacological intervention in isola-
tion on HRV in anxiety patients. First, Tucker et al. (110) examined
the effect of paroxetine (an SSRI) administration on HRV in 17 PD
patients. After 4 weeks of 20 mg of paroxetine daily, parasympa-
thetic activity was significantly increased in patients. This finding
stands in contrast to reports that SSRI treatments for major depres-
sion, including paroxetine, have no impact on HRV (13). Further,
the study reports only normalized units of HF HRV, a measure dif-
ficult to interpret when not reported alongside raw HF values (88).
Thus, the effect of SSRIs in isolation on HRV in anxiety patients has
yet to be properly studied, however, we can predict the effect will be
similar to the effect of SSRIs in treating major depression, that is,
negligible (13). Second, Baker et al. (111) examined the effect of
clonazepam (a benzodiazepine) administration on HRV relative
to placebo in 27 PD patients. Ten patients received clonazepam
while 17 received a placebo. Compared with placebo, patients
receiving clonazepam showed a significant decrease in HRV for
all time (SDANN, SDNN) and frequency (LF, HF) measures from
baseline to 4 weeks (all ps< 0.05). Treatment response was not
correlated with HRV. This result is consistent with previous stud-
ies observing reductions in HF HRV following benzodiazepine
administration (112–114).
The non-psychotropic treatments for anxiety disorders with
an evidence base are psychological and behavioral. The impact of
treating anxiety with cognitive behavioral therapy (CBT) on HRV
has been reported in a number of studies, with varying results.
Diveky, Prasko (115) reported that a 6-week CBT program on a
sample of 31 panic patients had no significant impact on HRV.
Mathewson, Schmidt (116) investigated the impact of 12 weeks
of 2 h group CBT sessions in 23 patients with SAD, reporting
a decrease in resting RSA levels over the course of the study. The
authors note this reduction in RSA may have been due to the antic-
ipation of a stressful task (i.e., anxiety provoking speech) during
testing sessions. Two studies have investigated the impact of expo-
sure based treatments on HRV in samples of flight phobics. Bornas
et al. (117) investigated the impact of an exposure treatment on
HRV in 20 patients, reporting that they exhibited a significant
reduction (p< 0.01) in HF HRV after six sessions of computer-
assisted or virtual reality exposure over 3 weeks, and curiously that
patients with lower pre-treatment HRV responded better to treat-
ment. In contrast to these findings, Busscher et al. (118) reported
on the impact of exposure (two 1-h flights) on HRV in 50 flight
phobics patients, observing a significant increase in RSA a find-
ing associated with a large effect size, even after a relatively brief
treatment. A possible explanation for this discrepancy could be
the differential impact between virtual versus in vivo exposure
on psychophysiological outcomes. Sack et al. (119) examined the
effect of eye movement desensitization and reprocessing (EMDR)
treatment on RSA in 11 patients with PTSD. Following an aver-
age of 4.7 (ranging from one to eight) EMDR sessions, there was
no difference in pre-treatment and post-treatment RSA; however,
there was a significant increase in RSA at 6 month follow-up. This
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reduction at follow-up was preceded by symptom reduction at
post-treatment assessment.
Finally, concerning studies that have investigated the effect
of concurrent psychotropic and non-psychotropic treatment on
HRV, Prasko e al. (46) examined the effect of both CBT and SSRIs
on HRV in 19 patients with PD. Following 18 group CBT ses-
sions and pharmacotherapy, all HRV power spectra increased,
with HF HRV increasing significantly. Garakani et al. (31) admin-
istered either 12 weeks of CBT alone or CBT with sertraline
(an SSRI), and in treatment responders, CBT alone was asso-
ciated with increases in HRV, but not the combined treatment.
Clearly, there is considerable heterogeneity in treatment studies
with respect to treatment type and the specific disorder being
treated. Thus, it is unsurprising that there is considerable vari-
ation in reports on HRV outcomes in response to treatment,
and it remains to be seen whether successful treatment of anx-
iety disorders will be paired with increases in HRV. However,
given that both anxiety and low HRV predict adverse cardio-
vascular outcomes, we recommend that anxiety patients consider
cardiovascular risk reduction strategies, such as exercise, smok-
ing cessation, dietary change, and meditation, in conjunction with
normal treatment.
This study has a number of advantages, including the appli-
cation of a standardized meta-analytic methodology to assess the
impact of anxiety disorders on HRV, examination of a range of
HRV measures, the inclusion of moderator analyses examining the
effect of frequently overlooked confounds including psychiatric
and medical co-morbidity, and medication status, assessment of
publication bias, and the application of strict inclusion/exclusion
criteria for the selection of studies. However, some limitations of
the present study are worth noting. There is a paucity of studies
reporting on the effects of GAD, OCD, SAD, and SP, placing limits
on the conclusions that can be drawn about the effect of these dis-
orders on HRV. This is particularly true for conclusions about HRV
and OCD. Only two studies reported on HRV and OCD, with one
study report no significant reductions (47), and one study report-
ing significant reductions with the caveat that the result may have
been related to the use of psychotropic medications (29). We also
found evidence for study heterogeneity, although this issue was
addressed in part, by conducting follow-up analyses to observe
the effect of specific anxiety disorders on HRV. Further, patients
with an anxiety disorder suffer from co-morbid depression in up
to 60% of cases (120), and although the present results indicate
that HRV of patients with psychiatric co-morbidity does not dif-
fer from those without such co-morbidity, it should be noted that
depression and co-morbid anxiety has been associated with greater
HRV reductions than depression alone (121), and depression and
co-morbid anxiety increases risk of all-cause mortality and CVD
two- to threefold (122). We observed a disproportionate num-
ber of studies on PD, highlighting the need for future studies on
other anxiety disorders. There is also a need for future studies
to consider the impact of evidence-based treatments for anxiety
disorders on HRV, allowing for the impact of symptom reduc-
tion on HRV to be determined and downstream effects on health
and well-being to be elucidated. Finally, there is a clear link both
between anxiety-disease and HRV-disease, and these have been
documented extensively by other authors. However, there are no
prospective studies reporting on all three factors, and how HRV
mediates the link between anxiety and disease. Future prospec-
tive studies examining the link between anxiety and disease while
reporting on HRV will be valuable in this regard.
In summary, the present results have important implications
for the long-term health and well-being of patients with a variety
of anxiety disorders, considering the body of work highlighting a
role for impaired vagal regulation as a risk factor for CVD and all-
cause mortality [see Ref. (9, 10, 123) for reviews]. In conclusion,
we advise clinicians to consider comprehensive cardiovascular risk
reduction strategies for anxiety patients.
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